Hemab Therapeutics Holdings, Inc. (COAG)

COAG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	87.97	74.41
Short-Term Investments	97.51	13.92
Cash & Short-Term Investments	185.49	88.33
Cash Growth	110.00%	-
Other Receivables	2.63	1.58
Receivables	2.63	1.58
Prepaid Expenses	4.44	3.33
Total Current Assets	192.55	93.24
Property, Plant & Equipment	1.7	2.57
Other Long-Term Assets	0.53	0.48
Total Assets	194.78	96.28
Accounts Payable	5.73	3.16
Accrued Expenses	3.96	2.47
Current Portion of Leases	0.65	0.67
Other Current Liabilities	0.34	0.39
Total Current Liabilities	10.68	6.69
Long-Term Leases	0.57	1.1
Other Long-Term Liabilities	-	0.02
Total Liabilities	11.25	7.8
Common Stock	0.01	0.01
Additional Paid-In Capital	5.04	3.03
Retained Earnings	-181.86	-117.95
Comprehensive Income & Other	0.18	-0.37
Total Common Equity	-176.64	-115.27
Shareholders' Equity	183.53	88.47
Total Liabilities & Equity	194.78	96.28
Total Debt	1.22	1.77
Net Cash (Debt)	184.27	86.55
Net Cash Growth	112.89%	-
Net Cash Per Share	4285.23	2012.88
Filing Date Shares Outstanding	0.04	0.04
Total Common Shares Outstanding	0.04	0.04
Working Capital	181.87	86.55
Book Value Per Share	-4107.79	-2680.77
Tangible Book Value	-176.64	-115.27
Tangible Book Value Per Share	-4107.79	-2680.77
Machinery	1.25	1.23
Leasehold Improvements	0.08	0.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q